Provided by Tiger Fintech (Singapore) Pte. Ltd.

Windtree Therapeutics, Inc.

0.9094
+0.05726.71%
Volume:220.16K
Turnover:192.78K
Market Cap:3.23M
PE:0.00
High:0.9123
Open:0.8700
Low:0.8304
Close:0.8522
Loading ...

Windtree Announces New Istaroxime Patent Filing for Preventing or Reducing the Risk of Acute Myocardial Arrhythmia

THOMSON REUTERS
·
09 Dec 2024

Windtree Announces New Istaroxime Patent Filing for Preventing or Reducing the Risk of Acute Myocardial Arrhythmia

GlobeNewswire
·
09 Dec 2024

H.C. Wainwright Sticks to Their Hold Rating for Windtree Therapeutics (WINT)

TIPRANKS
·
06 Dec 2024

Sector Update: Health Care Stocks Mixed Wednesday Afternoon

MT Newswires Live
·
05 Dec 2024

Windtree Therapeutics Engages Strategic Adviser to Evaluate Options for Cardiovascular Portfolio; Shares Fall

MT Newswires Live
·
05 Dec 2024

BRIEF-Windtree Announces Partnership With New Growth Advisors To Leverage Positive Phase 2 Istaroxime Study In Cardiogenic Shock For A Potential Strategic Transaction

Reuters
·
04 Dec 2024

Windtree Therapeutics Inc: Engaged New Growth Advisors as Its Strategic Advisor to Lead a Process in Respect of Windtree's Cardiovascular Portfolio

THOMSON REUTERS
·
04 Dec 2024

Windtree Announces Partnership With New Growth Advisors to Leverage Positive Phase 2 Istaroxime Study in Cardiogenic Shock for a Potential Strategic Transaction

THOMSON REUTERS
·
04 Dec 2024

Windtree Therapeutics Inc - May Receive up to $138 Million in Milestones From Lee's Pharmaceuticals

THOMSON REUTERS
·
04 Dec 2024

Windtree Therapeutics Inc - Lee's Pharmaceuticals to Start Phase 3 in Acute Heart Failure in H1 2025

THOMSON REUTERS
·
04 Dec 2024

Windtree: IF a Deal Is Consummated for Cardiovascular Portfolio, Plans to Use Some Proceeds to Support Advancement of Oncology Platform

THOMSON REUTERS
·
04 Dec 2024

Windtree Announces Partnership with New Growth Advisors to Leverage Positive Phase 2 Istaroxime Study in Cardiogenic Shock for a Potential Strategic Transaction

GlobeNewswire
·
04 Dec 2024

Windtree Therapeutics Q3 EPS $(4.23) Up From $(15.47) YoY

Benzinga
·
28 Nov 2024

Windtree Therapeutics Reports Third Quarter 2024 Financial Results and Provides Key Business Updates

THOMSON REUTERS
·
28 Nov 2024

Windtree Therapeutics: Believe We Have Sufficient Resources Available to Fund Business Operations Through Jan 2025

THOMSON REUTERS
·
28 Nov 2024

Windtree Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary

Reuters
·
27 Nov 2024

BUZZ-Windtree slides on CEO retirement

Reuters
·
15 Nov 2024

Windtree Therapeutics Inc - Craig Fraser to Remain as Chairman of Windtree Therapeutics

THOMSON REUTERS
·
14 Nov 2024

Windtree Therapeutics Inc - Craig Fraser to Retire as CEO of Windtree Therapeutics Effective Dec 1, 2024

THOMSON REUTERS
·
14 Nov 2024

Windtree Announces Leadership Transition Plan With Industry Veterans

THOMSON REUTERS
·
14 Nov 2024